Related Experiment Video
Updated: Jul 15, 2026
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Results from the north cyprus thalassemia prevention program.
1North Cyprus Thalassaemia Centre, Nicosia,Cyprus. gulsenbozkurt@yahoo.com
Hemoglobin
|May 9, 2007
Summary
Cyprus successfully reduced thalassemia births through a comprehensive prevention program. This initiative, starting in 1979, led to a significant decline in affected newborns and improved patient quality of life.
Area of Science:
- Medical Genetics
- Public Health
- Hematology
Background:
- Thalassemia posed a significant health challenge in Cyprus.
- Early scientific efforts began in 1976, leading to the recognition of prevention as a key strategy.
- The hereditary nature of thalassemia highlighted the potential for effective prevention programs.
Purpose of the Study:
- To halt the birth of newborns with thalassemia.
- To establish robust treatment facilities for existing thalassemia patients.
- To implement a comprehensive thalassemia prevention program in Cyprus.
Main Methods:
- Screening of high-risk families initiated in 1979.
- Compulsory premarital screening enacted by law in 1980.
- Introduction of prenatal diagnosis via fetal blood sampling in 1984, later replaced by DNA techniques in 1991.
Main Results:
- Affected birth rates dramatically decreased post-1984, from 18-20 cases annually to minimal occurrences.
- Between 1991-2001, only five thalassemia births were recorded.
- No thalassemia births have occurred in the last five years.
- Thalassemia patients experience improved longevity and quality of life due to advanced treatments.
Conclusions:
- The thalassemia prevention program in Cyprus has been highly effective in reducing birth rates.
- Modern treatment modalities have significantly enhanced the quality of life and lifespan for thalassemia patients.
- A majority of treated thalassemia patients are now integrated into society, with many married and having children.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...